论文部分内容阅读
目的探讨减低剂量柔红霉素联合阿糖胞苷(DA)方案治疗急性非淋巴细胞白血病(ANLL)患者的疗效和不良反应。方法 28例老年ANLL患者分别以减低剂量DA方案、标准方案治疗,比较两组病例的临床疗效、不良反应、病死率的差异。结果减低剂量DA方案组与标准剂量DA组对比完全缓解(CR)率、部分缓解(PR)率差异无统计学意义(P>0.05)。减低剂量DA方案组骨髓抑制4度(白细胞减少、血小板减少)率低于标准剂量DA方案组(P<0.05),非血液学毒性可耐受,治疗相关死亡率低于标准剂量DA。患者多死于骨髓抑制期继发感染、出血(内脏出血)。结论减低剂量DA方案是老年ANLL患者的可以耐受且疗效良好的治疗方案。
Objective To investigate the efficacy and adverse reactions of daunorubicin combined with cytarabine (DA) regimen in the treatment of patients with acute nonlymphocytic leukemia (ANLL). Methods 28 cases of elderly patients with ANLL were treated with reduced-dose DA regimen and standard regimen. The clinical efficacy, adverse reactions, and mortality were compared between the two groups. Results There was no significant difference in complete remission (CR) rate and partial remission (PR) rate between DA group and standard DA group (P>0.05). The rate of bone marrow suppression in the reduced-dose DA regimen was 4 degrees (leucopenia, thrombocytopenia) lower than that of the standard DA regimen (P<0.05). Nonhematologic toxicity was tolerable, and the treatment-related mortality was lower than the standard DA. The patient died of secondary infection and hemorrhage during myelosuppression (visceral hemorrhage). Conclusions The reduced dose DA regimen is a well-tolerated and effective therapeutic regimen in elderly patients with ANLL.